FIME / WHX Miami vs Hospitalar for Exhibitors
Side-by-side data and our editorial take on which conference is the right exhibit investment for your medical device.
If you exhibit medical devices, FIME / WHX Miami and Hospitalar are likely both on your shortlist. Both serve overlapping clinical buyers, but the audience composition, booth economics, and exhibit floor experience differ in ways that materially affect ROI. FIME / WHX Miami draws 15,000 attendees with an estimated all-in 10×10 of TBD. Hospitalar draws 91,000 attendees at TBD all-in. Below is the side-by-side data plus our editorial take on which conference fits which kind of exhibitor.
| 7.2 FIME / WHX Miami | 9.5 Hospitalar | |
|---|---|---|
| Score | ||
| Buzzbox Score | 7.2 (Strong) | 9.5 (Exceptional) |
| Event Details | ||
| Dates | June 17-19, 2026 | May 19-22, 2026 |
| Location | Miami Beach Convention Center, Miami Beach, FL | Sao Paulo Expo Exhibition & Convention Center, Sao Paulo, Brazil |
| Scale | large | mega |
| Audience | ||
| Attendees | 15,000 | 91,000 |
| Exhibitors | — | — |
| Purchasing authority | ~50% | ~55% |
| Effective buyers | 7,500 | 50,050 |
| Costs | ||
| $/sqft | — | — |
| 10×10 space | — | — |
| All-in estimate | — | — |
| Cost per buyer | — | — |
Why exhibit at FIME / WHX Miami
The #1 show for reaching Latin American and Caribbean healthcare buyers from US soil. Miami location eliminates visa and logistics complexity that Hospitalar (Brazil) presents. 120+ countries represented, $556M in business value. If you want LatAm distribution without leaving the US, this is it.
Why exhibit at Hospitalar
The #1 gateway to Latin America's healthcare markets. Brazil alone is the 6th largest medical device market globally. 91,000+ attendees with significant government procurement officers make this essential for companies expanding into LatAm.
Why skip FIME / WHX Miami
Not a clinical/scientific conference -- no educational sessions or CME credits drive traffic. US domestic buyers have better options at specialty-specific shows. Attendance is lower-density than the big mega shows (15k vs 90k at Hospitalar), so lead volume per dollar is lower if your primary target is Brazil specifically.
Why skip Hospitalar
Brazil's ANVISA regulatory pathway is complex and slow. Companies without existing Brazilian registration or a local importer/distributor will collect leads they can't convert for 12-24 months. Portuguese-language materials are essential -- English-only booths underperform badly.